Words by Isabel O’Brien
Danish pharmaceutical giant Novo Nordisk has unveiled significant changes to its executive leadership team, effective 3 April 2025, following the departure of Camilla Sylvest, Executive Vice President of Commercial Strategy & Corporate Affairs. Sylvest leaves after a 28-year career at the company.
Ludovic Helfgott, currently EVP of Rare Disease, will expand his remit to oversee Product & Portfolio Strategy, encompassing commercial strategy, medical affairs and business development across all therapy areas. Helfgott, who joined Novo Nordisk in 2019 from AstraZeneca, has been instrumental in building the company’s rare disease portfolio and will now play a broader strategic role.
Thilde Hummel Bøgebjerg, a 18-year Novo Nordisk veteran, has been promoted to EVP of Quality, IT & Environmental Affairs, reflecting her extensive experience in supply chain and emerging technologies. Tania Sabroe, EVP of People & Organisation, will additionally lead Global Communication.
The reshuffle comes as Novo Nordisk navigates the high demand for its GLP-1 therapies and aims to strengthen its rare disease division, a priority under its CEO Lars Fruergaard Jørgensen.
The updated executive team now comprises 10 members, including Helfgott, Bøgebjerg and Sabroe, alongside longstanding leaders like CFO Karsten Munk Knudsen.
